Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Feb;95(2):293-301.
doi: 10.1111/cge.13474. Epub 2018 Dec 7.

Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study

Affiliations
Randomized Controlled Trial

Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study

Nina Beri et al. Clin Genet. 2019 Feb.

Abstract

Telephone disclosure of cancer genetic test results is noninferior to in-person disclosure. However, how patients who prefer in-person communication of results differ from those who agree to telephone disclosure is unclear but important when considering delivery models for genetic medicine. Patients undergoing cancer genetic testing were recruited to a multicenter, randomized, noninferiority trial (NCT01736345) comparing telephone to in-person disclosure of genetic test results. We evaluated preferences for in-person disclosure, factors associated with this preference and outcomes compared to those who agreed to randomization. Among 1178 enrolled patients, 208 (18%) declined randomization, largely given a preference for in-person disclosure. These patients were more likely to be older (P = 0.007) and to have had multigene panel testing (P < 0.001). General anxiety (P = 0.007), state anxiety (P = 0.008), depression (P = 0.011), cancer-specific distress (P = 0.021) and uncertainty (P = 0.03) were higher after pretest counseling. After disclosure of results, they also had higher general anxiety (P = 0.003), depression (P = 0.002) and cancer-specific distress (P = 0.043). While telephone disclosure is a reasonable alternative to in-person disclosure in most patients, some patients have a strong preference for in-person communication. Patient age, distress and complexity of testing are important factors to consider and requests for in-person disclosure should be honored when possible.

Keywords: cancer genetic testing; genetic counseling; in-person disclosure preference; result disclosure; telephone disclosure.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES: All authors report that there are no conflicts of interest to disclose.

Figures

Figure 1 –
Figure 1 –. Consort Diagram
*Individuals approached prior to Non-BRCA 1/2 and Multigene Testing Adaptation **Multiple reasons for decline were reported per participant ‡ Reflects individuals who were: disclosed by telephone at participant’s behest (N=31), disclosed by telephone due to illness/financial burden (N=3) and received results in-person with a Non-COGENT provider (N=3) ¶Survey not completed within 0–7 days

References

    1. Robson ME, Bradbury AR, Arun B, et al.: American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 33:3660–7, 2015 - PubMed
    1. Goldman JS, Hahn SE, Catania JW, et al.: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 13:597–605, 2011 - PMC - PubMed
    1. Gersh BJ, Maron BJ, Bonow RO, et al.: 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:2761–96, 2011 - PubMed
    1. Tchan M, Savige J, Patel C, et al.: KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. Semin Nephrol 35:545–549 e2, 2015 - PubMed
    1. (ACMG) ACoMGaG: Policy Statement: Points to Consider in the Clinical Application of Genomic Sequencing, 2012 - PubMed

Publication types

MeSH terms

Substances

Associated data